Altus Pharmaceuticals, a developer of oral and injectable protein therapeutics for chronic gastrointestinal and metabolic disorders, registered with the SEC for an initial public offering Monday morning. The Cambridge, MA-based company has two main product candidates in its pipeline. Merrill Lynch and Morgan Stanley will be the lead underwriters on the deal and terms and timing have yet to be determined.
